Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Next Previous
Trial Profile

A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Posterior uveitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors EyePoint Pharmaceuticals

Most Recent Events

  • 01 Jun 2022 Results assessing Prevention of non-infectious uveitis of the posterior segment (NIU-PS) recurrence using 0.2 mug/day fluocinolone acetonide implant over 3 years, published in the Eye.
  • 23 Sep 2020 According to an Alimera Sciences media release, 3-year fellow eye subgroup analysis data from this trial will be featured during the EURETINA 2020 Virtual Congress.
  • 08 Sep 2020 According to an Alimera Sciences Scottish Medicines Consortium (SMC), after completing its assessment and review, has accepted (per label) ILUVIEN for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).The decision came following a review of a cost-utility analysis for the prevention of relapse in recurrent non-infectious uveitis based on results from this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top